Press release
Methylmalonic Acidemia Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies -Logic Biotherapeutics, Moderna, HemoShear Therapeutics, Target Pharma Solutions.
Methylmalonic Acidemia Market
Download Sample Report to know more @ https://www.delveinsight.com/sample-request/methylmalonic-acidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Methylmalonic Acidemia Overview
Methylmalonic acidemia is a disorder in which the body cannot break down certain proteins and fats. The result is a buildup of a substance called methylmalonic acid in the blood. This condition is passed down through families. It is one of several conditions called an "inborn error of metabolism. There are two types of methylmalonic acidemia (MMA): cobalamin disorders and MUT deficiencies. One of the ways these two types of MMA differ is their response to vitamin B-12. MUT deficiencies are considered non-vitamin B-12 responsive. Cobalamin deficiencies are vitamin B-12 responsive.
Learn more about Methylmalonic Acidemia @ https://www.delveinsight.com/report-store/methylmalonic-acidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
The key Methylmalonic Acidemia companies working in the treatment landscape include Logic Biotherapeutics, Moderna, HemoShear Therapeutics, Target Pharma Solutions, and many others.
The key Methylmalonic Acidemia therapies in the pipeline include hLB-001, HST5040, SEL-302, BBP-671, and many others.
Methylmalonic Acidemia Treatment Market
Medication treatment consists of cobalamin (vitamin B12) given as an injection, carnitine, and antibiotics. The diet is protein-restricted to limit the intake of isoleucine, threonine, methionine, and valine because these substances can turn into methylmalonic acid in an affected patient
Learn more about the treatment market for the report
https://www.delveinsight.com/report-store/methylmalonic-acidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
The Report Covers the Methylmalonic Acidemia Epidemiology Segmented by:
Methylmalonic Acidemia Prevalent cases
Methylmalonic Acidemia Incident Cases
Methylmalonic Acidemia treatment cases
Methylmalonic Acidemia Diagnosed cases
Methylmalonic Acidemia Dug Profile and Companies Covered
Logic Biotherapeutics- hLB-001
HemoShear Therapeutics- HST5040
CoA Therapeutics- SEL-302
Sanofi- BBP-671
And many others.
Learn more about the Key Companies and Emerging Therapies @https://www.delveinsight.com/sample-request/methylmalonic-acidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Table of Contents
Key Insights
Methylmalonic Acidemia Introduction
Executive Summary of Methylmalonic Acidemia
Disease Background and Overview
Methylmalonic Acidemia Epidemiology and Patient Population
Methylmalonic Acidemia Emerging Therapies
Methylmalonic Acidemia Market Outlook
Methylmalonic Acidemia Market Access and Reimbursement of Therapies
Methylmalonic Acidemia Market Drivers
Methylmalonic Acidemia Market Barriers
Appendix
Methylmalonic Acidemia Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @https://www.delveinsight.com/sample-request/methylmalonic-acidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Related Reports
Methylmalonic Acidemia Epidemiology Forecast 2032
Methylmalonic Acidemia Pipeline Insight 2023
DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Methylmalonic Acidemia Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies -Logic Biotherapeutics, Moderna, HemoShear Therapeutics, Target Pharma Solutions. here
News-ID: 3280388 • Views: …
More Releases from DelveInsight Business Research LLP
Paroxysmal Nocturnal Hemoglobinuria Treatment Pipeline Shows Strong Momentum as …
DelveInsight's, "Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Haemoglobinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies …
DelveInsight's "Sarcopenia Pipeline Insight 2026" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Sarcopenia pipeline landscape. It covers the Sarcopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sarcopenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Sarcopenia Research. Learn more about…
Thymidine Kinase 2 Deficiency Market is projected to grow at a CAGR of 50% by 20 …
DelveInsight's "Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Thymidine Kinase 2 Deficiency epidemiology, market, and clinical development understanding, Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Thymidine Kinase 2 Deficiency therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom,…
Lupus Nephritis Clinical Trial Pipeline Appears Robust With 35+ Key Pharma Compa …
DelveInsight's "Lupus Nephritis Pipeline Insight 2026" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
More Releases for Methylmalonic
2025-2034 Methylmalonic Acidemia (MMA) Market Evolution: Disruptions, Innovation …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Methylmalonic Acidemia (MMA) Market Through 2025?
The domain pertaining to methylmalonic acidemia (mma) has experienced robust expansion recently, projected to advance from a valuation of $9.39 billion in 2024 to $9.94 billion the following year, reflecting a compound annual growth rate (CAGR)…
Methylmalonic Acidemia Market trends, Diagnosis, and Treatment Landscape
Methylmalonic Acidemia (MMA) is a rare inherited metabolic disorder resulting from defects in the metabolism of certain amino acids, cholesterol, and fatty acids. It is typically caused by mutations in genes responsible for the enzyme methylmalonyl-CoA mutase or related pathways. Patients with MMA are unable to properly break down specific compounds, leading to accumulation of toxic substances in the blood, which can result in developmental delays, recurrent metabolic crises, and…
Methylmalonic Acid Market: An In-Depth Analysis
In 2024, the market was valued at approximately USD 250 million and is projected to reach around USD 400 million by 2033, reflecting a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
Methylmalonic Acid Market Overview
Methylmalonic acid serves as a crucial biomarker in clinical settings, aiding in the diagnosis of conditions such as methylmalonic acidemia and other vitamin B12-related disorders. The market's growth is fueled by the rising…
Methylmalonic Acidemia (MMA) Market Size Projected To Reach $12.5 Billion By 203 …
The Methylmalonic Acidemia (MMA) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Methylmalonic Acidemia (MMA) Market?
The market for methylmalonic acidemia (MMA) has experienced robust growth in the past few years. The size of the market is forecasted to…
Methylmalonic Acid Market Will Generate Record Revenue by 2029
The Methylmalonic Acid Market is anticipated to grow at a significant CAGR during the forecast period. Methylmalonic acid (MMA) is a substance created by the human body when it digests protein. The amount of vitamin B12 in the body controls the production of MMA in the body. A high amount of MMA typically means a deficiency of vitamin B12.?The major factor driving the growth of the market during the forecast…
Methylmalonic Acidemia Market to Show a Rise During the Forecast Period asserts …
DelveInsight's "Methylmalonic Acidemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Methylmalonic Acidemia, historical and forecasted epidemiology as well as the Methylmalonic Acidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Methylmalonic Acidemia market report provides current treatment practices, emerging drugs, Methylmalonic Acidemia market share of the individual therapies, and current and forecasted Methylmalonic Acidemia market size…
